Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Costs, Cognitive Abilities and Quality of Life After Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement (CCQ)

11. November 2016 aktualisiert von: Francesco Saia, MD, PhD, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Multicenter, prospective, observational study in aortic stenosis (AS) patients undergoing transcatheter aortic valve implantation (TAVI) or high-risk patients undergoing aortic valve replacement (AVR).

The objectives of the study are:

  1. Description of neurocognitive status before and after transcatheter aortic valve implantation and aortic valve replacement procedures
  2. Description of Quality of Life (QoL) after these procedures
  3. Defining the relevance of baseline psychological, emotional and cognitive factors on the outcomes associated to the different treatment modalities
  4. Assessment of costs associated to each of the above mentioned strategies of treatment, including costs of the index hospitalization and costs of follow-up.

Studienübersicht

Detaillierte Beschreibung

In Italy, a nation-wide observational study endorsed by the Superior Institute of Health has been previously launched in order to evaluate appropriateness and effectiveness of aortic valve replacement (AVR) and transcatheter aortic valve implantation (TAVI) procedures: the OBservational Study of Effectiveness of AVR-TAVI procedures for severe Aortic steNosis Treatment (OBSERVANT). The present study was designed to complement the national survey on TAVI and AVR procedures including data about costs, cognitive functions and quality of life after these procedures. This integrated framework may help defining the relevance of baseline psychological, emotional and cognitive factors on the outcomes associated to the different treatment modalities and, on the other hand, should enable accurate evaluation of the impact of each kind of treatment on quality of life and neuropsychological functions. These elements could also represent relevant keys to decision-making to the different therapeutic strategies. In addition, we aim to ascertain costs associated to each of the above mentioned strategies of treatment, including costs of the index hospitalization and follow-up costs. Costs estimate, combined to the integrated physical and mental health status outcome for each treatment modality, may represent the background for subsequent cost-effectiveness analyses.

All consecutive patients undergoing transcatheter aortic valve implantation or aortic valve replacement (if age ≥ 80 years or Logistic Euroscore ≥ 15%) for aortic stenosis at participating centers during the period of enrollment will be included in the registry, after release of written informed consent. Allocation of patients to different treatment groups will be performed jointly by a cardiologist and a cardiac surgeon on the basis of a complete clinical framework, independently from the present study and in accordance with available guidelines. Type of treatment (for example, access site for TAVI, type of prosthesis…) will be decided by the physicians based on local clinical practice and general principles of good clinical practice.

The administration of neurocognitive and quality of life questionnaires will be performed before the procedure and after 3 months and 1 year by trained personnel following standard operation procedures defined by a coordinating unit. A telephone and web-based support for operators will be available throughout the entire duration of the study. A common methodology for data collection and analysis is defined to guarantee data reliability and homogeneity of assessments among the participating units. The cost analysis will be coordinated by the Regional Healthcare and Social Agency of the Emilia Romagna Region.

Data will be collected in a web-based database (OBSERVANT) through dedicated Case Records Forms and a final database will be built by merging this database with a separate database for costs and Hospital Discharge Records and Mortality Registry databases.

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

518

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Bologna, Italien, 40138
        • Institute of Cardiology, Azienda Ospedaliero-Universitaria di Bologna

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind
  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

All consecutive patients undergoing TAVI or AVR for AS at participating centers during the period of enrollment

Beschreibung

Inclusion Criteria:

  • All consecutive patients undergoing TAVI at participating centers during the period of enrollment
  • All consecutive patients aged ≥80 years or with Logistic Euroscore ≥15% undergoing AVR at participating centers during the period of enrollment

Exclusion Criteria:

  • Absence of informed consent

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: Kohorte
  • Zeitperspektiven: Interessent

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Transcatheter aortic valve implantation
All consecutive patients undergoing TAVI at participating centres during study period
Patients undergoing TAVI with transfemoral, transapical, or any other vascular access
Andere Namen:
  • Edwards Sapien XT
  • Corevalve
  • Acurate-TA
Aortic Valve Replacement
All consecutive patients aged ≥ 80 years or with Logistic Euroscore≥ 15% undergoing AVR for AS at participating centers during the period of enrollment
Surgical AVR, with all kind of commercially available prosthesis (stented, stentless, mechanical)

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Mini Mental State Examination (MMSE)
Zeitfenster: baseline, 3-month, 12-month
Changes in cognitive function after transcatheter aortic valve implantation and surgical aortic valve replacement
baseline, 3-month, 12-month
Hospital Anxiety and Depression Scale (HADS)
Zeitfenster: baseline, 3-month, 12-month
Changes of emotional status after transcatheter aortic valve implantation and surgical aortic valve replacement
baseline, 3-month, 12-month
Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Zeitfenster: baseline, 3-month, 12-month
Changes in quality of life after transcatheter aortic valve implantation and surgical aortic valve replacement
baseline, 3-month, 12-month
In-hospital costs
Zeitfenster: Participants will be followed for the duration of hospital stay, an expected average of 10 days for transcatheter aortic valve implantation and 2 weeks for surgical Aortic Valve Replacement
Calculation of precise hospital costs for transcatheter aortic valve implantation and surgical Aortic Valve Replacement, including costs of hospitalization, drugs and devices.
Participants will be followed for the duration of hospital stay, an expected average of 10 days for transcatheter aortic valve implantation and 2 weeks for surgical Aortic Valve Replacement

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Myocardial infarction
Zeitfenster: 30-day, 12-month and up to 2-year (longest available follow-up)
Incidence of myocardial infarction
30-day, 12-month and up to 2-year (longest available follow-up)
Stroke
Zeitfenster: 30-day, 12-month and up to 2-year (longest available follow-up)
Incidence of stroke
30-day, 12-month and up to 2-year (longest available follow-up)
Pace-maker implantation
Zeitfenster: 30-day, 12-month
Need for permanent pacing
30-day, 12-month
Vascular complications
Zeitfenster: 30-day
Incidence of vascular complications as defined by the VARC
30-day
Bleedings
Zeitfenster: 30-day
Incidence of bleedings as defined by the VARC
30-day
Acute kidney injury
Zeitfenster: 30-day
Incidence of AKI as defined by the VARC
30-day
Follow-up costs
Zeitfenster: 12-month
Evaluation of costs during follow-up, including new hospital admissions, outpatient clinic and drugs
12-month

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Dezember 2011

Primärer Abschluss (Tatsächlich)

1. Januar 2016

Studienabschluss (Tatsächlich)

1. Januar 2016

Studienanmeldedaten

Zuerst eingereicht

8. Mai 2013

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

9. Mai 2013

Zuerst gepostet (Schätzen)

13. Mai 2013

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

15. November 2016

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2016

Zuletzt verifiziert

1. November 2016

Mehr Informationen

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

3
Abonnieren